SEARCH

SEARCH BY CITATION

References

  • 1
    Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 4152.
  • 2
    Samuel D, Feray C. Recurrent hepatitis C after liver transplantation: Clinical and therapeutical issues. J Viral Hepat 2000; 7: 8792.
  • 3
    Wright TL, Combs C, Kim M et al. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation. Hepatology 1994; 20 (4 Pt 1): 773779.
  • 4
    Gane EJ, Portmann BC, Naoumov NV et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815820.
  • 5
    Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: Systematic review of antiviral therapy. Transplantation 2005; 79: 261268.
  • 6
    Neff GW, O'Brien CB, Nery J et al. Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection. Liver Transpl 2004; 10: 14971503.
  • 7
    Curry MP. Hepatitis B and hepatitis C viruses in liver transplantation. Transplantation 2004; 78: 955963.
  • 8
    Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358: 958965.
  • 9
    Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 10
    Neff GW, Montalbano M, O'Brien CB et al. Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy. Transplantation 2004; 78: 13031307.
  • 11
    Toniutto P, Fabris C, Fumo E et al. Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. J Gastroenterol Hepatol 2005; 20: 577582.
  • 12
    Babatin M, Schindel L, Burak KW. Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: From a Canadian experience to recommendations for therapy. Can J Gastroenterol 2005; 19: 359365.
  • 13
    Neuberger J. Treatment of hepatitis C virus infection in the allograft. Liver Transpl 2003; 9: S101S108.
  • 14
    Castells L, Vargas V, Allende H et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 5359.
  • 15
    Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004; 10: 868871.
  • 16
    Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35: 30423044.
  • 17
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: A pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669674.
  • 18
    Roche B, Samuel D. Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C. Transpl Int 2005; 17: 759766.
  • 19
    Zeuzem S, Feinman SV, Rasenack J et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 16661672.
  • 20
    Heathcote EJ, Shiffman ML, Cooksley WG et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000; 343: 16731680.
  • 21
    Lindsay KL, Trepo C, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395403.
  • 22
    Bruchfeld A, Lindahl K, Stahle L, Soderberg M, Schvarcz R. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003; 18: 15731580.
  • 23
    Lindahl K, Schvarcz R, Bruchfeld A, Stahle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepat 2004; 11: 8487.
  • 24
    Ishak K, Baptista A, Bianchi L et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696699.
  • 25
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226231.
  • 26
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289293.
  • 27
    Chalasani N, Manzarbeitia C, Ferenci P et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials. Hepatology 2005; 41: 289298.
  • 28
    Shergill AK, Khalili M, Straley S et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118124.
  • 29
    Zeuzem S, Schmidt JM, Lee JH, Von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245252.
  • 30
    Tsubota A, Arase Y, Someya T et al. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load. J Med Virol 2005; 75: 2734.
  • 31
    Enomoto M, Nishiguchi S, Kohmoto M et al. Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. J Viral Hepat 2004; 11: 448454.
  • 32
    Zeuzem S, Herrmann E, Lee JH et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 14381447.
  • 33
    Charlton M, Seaberg E, Wiesner R et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823830.
  • 34
    Gane EJ, Maertens G, Ducatteeuw A et al. Antibodies to hepatitis C virus envelope proteins correlate with hepatitis C viraemia after liver transplantation. Transplantation 1999; 67: 7884.
  • 35
    Neumann AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 2835.
  • 36
    Mulhall BP, Younossi Z. Impact of adherence on the outcome of antiviral therapy for chronic hepatitis C. J Clin Gastroenterol 2005; 39 (1 Suppl.): S23S27.
  • 37
    Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: A nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7: 863869.
  • 38
    Alberti AB, Belli LS, Airoldi A et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: A pragmatic study. Liver Transpl 2001; 7: 870876.
  • 39
    Gopal DV, Rabkin JM, Berk BS et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7: 181190.
  • 40
    Firpi RJ, Abdelmalek MF, Soldevila-Pico C et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8: 10001006.
  • 41
    Lavezzo B, Franchello A, Smedile A et al. Treatment of recurrent hepatitis C in liver transplants: Efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin. J Hepatol 2002; 37: 247252.
  • 42
    Shakil AO, McGuire B, Crippin J et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36: 12531258.
  • 43
    Samuel D, Bizollon T, Feray C et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: A randomized study. Gastroenterology 2003; 124: 642650.
  • 44
    Berenguer M, Prieto M, Palau A et al. Recurrent hepatitis C genotype 1b following liver transplantation: Treatment with combination interferon-ribavirin therapy. Eur J Gastroenterol Hepatol 2004; 16: 12071212.
  • 45
    Giostra E, Kullak-Ublick GA, Keller W et al. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004; 17: 169176.
  • 46
    Mukherjee S, Lyden E, McCashland TM, Schafer DF. Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: Cohort study of 38 patients. J Gastroenterol Hepatol 2005; 20: 198203.
  • 47
    Abdelmalek MF, Firpi RJ, Soldevila-Pico C et al. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl 2004; 10: 199207.
  • 48
    Stravitz RT, Shiffman ML, Sanyal AJ et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10: 850858.